Effects of CB2 and TRPV1 receptors’ stimulation in pediatric acute T-lymphoblastic leukemia
Metrics: PDF 520 views | HTML 861 views | ?
Francesca Punzo1,2, Iolanda Manzo2, Chiara Tortora2, Elvira Pota1, Velia D’ Angelo1, Giulia Bellini2, Alessandra Di Paola1, Federica Verace1, Fiorina Casale1 and Francesca Rossi1
1Department of Women, Child and General and Specialist Surgery, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy
2Department of Experimental Medicine, Division of Pharmacology “Leonardo Donatelli”, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy
Francesca Rossi, email: firstname.lastname@example.org
Keywords: oncogene; MYB; SKI; transcriptional regulation; acute myeloid leukemia
Received: August 24, 2017 Accepted: March 21, 2018 Published: April 20, 2018
T-Acute Lymphoblastic Leukemia (T-ALL) is less frequent than B-ALL, but it has poorer outcome. For this reason new therapeutic approaches are needed to treat this malignancy.
The Endocannabinoid/Endovanilloid (EC/EV) system has been proposed as possible target to treat several malignancies, including lymphoblastic diseases. The EC/EV system is composed of two G-Protein Coupled Receptors (CB1 and CB2), the Transient Potential Vanilloid 1 (TRPV1) channel, their endogenous and exogenous ligands and enzymes. CB1 is expressed mainly in central nervous system while CB2 predominantly on immune and peripheral cells, therefore we chose to selectively stimulate CB2 and TRPV1.
We treated T-ALL lymphoblasts derived from 4 patients and Jurkat cells with a selective agonist at CB2 receptor: JWH-133 [100 nM] and an agonist at TRPV1 calcium channel: RTX [5 uM] at 6, 12 and 24 hours. We analyzed the effect on apoptosis and Cell Cycle Progression by a cytofluorimetric assays and evaluated the expression level of several target genes (Caspase 3, Bax, Bcl-2, AKT, ERK, PTEN, Notch-1, CDK2, p53) involved in cell survival and apoptosis, by Real-Time PCR and Western Blotting.
We observed a pro-apoptotic, anti-proliferative effect of these compounds in both primary lymphoblasts obtained from patients with T-ALL and in Jurkat cell line. Our results show that both CB2 stimulation and TRPV1 activation, can increase the apoptosis in vitro, interfere with cell cycle progression and reduce cell proliferation, indicating that a new therapeutic approach to T-cell ALL might be possible by modulating CB2 and TRPV1 receptors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.